August 7, 2026- The U.S. Food and Drug Administration has approved a first-of-its-kind flu vaccine made with messenger RNA technology, according to Healthcare Dive. Moderna’s flu vaccine for people aged 50 and older, the company said on Wednesday, marks the first approval of a messenger RNA-based vaccine for seasonal flu, according to Reuters. The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, and an accelerated approval for those 65 years and older. The shot’s clearance in those 65 or older was handed out under an “accelerated” approval that’s contingent on results from a postmarketing study.